kabutan

KISSEI PHARMA shares extend gains as major domestic brokerage initiates coverage with top rating

Thu Apr 2, 2026 1:52 pm JST Catalyst

KISSEI PHARMACEUTICAL CO.,LTD. <4547> extended its gains. SMBC Nikko Securities initiated coverage on the company's shares on the 1st with a top rating of "1" on its three-tier scale. The target price was set at \5,500. The brokerage cited the following factors for its positive rating: (1) stable growth is expected through the fiscal year ending March 2032, driven by growth in its core rare disease pipeline; (2) the company's proprietary new drugs, including uterine fibroid treatment "linzagolix" and Parkinson's disease treatment "matsupexole," are beginning to emerge, with expectations for improved performance through overseas expansion; and (3) improvements in capital efficiency and support for the share price from high dividend yields.

Source: MINKABU PRESS

Related Articles